GLS - Gelesis Holdings, Inc. Stock Price and Quote

GLS [NYSE]

Index	-	P/E	-	EPS (ttm)	-1.33	Insider Own	0.30%	Shs Outstand	72.77M	Perf Week	-21.04%
Market Cap	28.05M	Forward P/E	-	EPS next Y	-0.27	Insider Trans	33.23%	Shs Float	35.02M	Perf Month	-33.73%
Income	-	PEG	-	EPS next Q	-0.26	Inst Own	37.50%	Short Float / Ratio	1.46% / 1.54	Perf Quarter	-27.10%
Sales	26.03M	P/S	1.08	EPS this Y	-396.40%	Inst Trans	5.25%	Short Interest	0.51M	Perf Half Y	-84.83%
Book/sh	-0.05	P/B	-	EPS next Y	78.90%	ROA	-	Target Price	-	Perf Year	-95.83%
Cash/sh	0.19	P/C	1.13	EPS next 5Y	-	ROE	-	52W Range	0.11 - 6.25	Perf YTD	-41.51%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	32.00%	52W High	-97.28%	Beta	-
Dividend %	-	Quick Ratio	0.50	Sales past 5Y	-	Gross Margin	-	52W Low	54.41%	ATR	0.05
Employees	101	Current Ratio	0.70	Sales Q/Q	116.10%	Oper. Margin	-	RSI (14)	39.13	Volatility	54.55% 23.36%
Optionable	No	Debt/Eq	-	EPS Q/Q	73.00%	Profit Margin	-	Rel Volume	6.62	Prev Close	0.21
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	332.95K	Price	0.17
Recom	3.00	SMA20	-29.57%	SMA50	-43.11%	SMA200	-81.06%	Volume	324,939	Change	-19.08%

Jan-05-23 07:00AM	Gelesis to Participate in the 25th Annual ICR Conference Business Wire -8.00%
Nov-21-22 07:00AM	Gelesis Reports Upcoming Participation in Wolfe Researchs Annual Consumer Growth Conference Business Wire +15.36%
Nov-18-22 06:00PM	Gelesis Receives Notice of NYSE Market Capitalization Listing Rule Non-Compliance Business Wire +6.82%
Nov-14-22 07:00AM	Gelesis Reports Third Quarter 2022 Results Business Wire +5.36%
Nov-07-22 07:00AM	Gelesis to Report Third Quarter 2022 Financial Results on November 14, 2022 Business Wire
06:00PM	Loading…
Nov-04-22 06:00PM	Gelesis Receives Notice of NYSE Trading Share Price Listing Rule Non-Compliance Business Wire
Nov-02-22 07:30AM	Data Presented at Obesity Week Demonstrate that Gelesis Investigational Clinical-Stage Oral Superabsorbent Hydrogel Gel-B Preferentially Enhances the Growth of Akkermansia muciniphila in Preclinical Models Compared to Prebiotics Business Wire -20.53%
Nov-01-22 05:24PM	Dr. Frank Greenway to Present Data from the LIGHT-UP Study with Gelesis Oral Hydrogel Treatment GS200 at Obesity Week Business Wire
Sep-08-22 07:00AM	Gelesis to Participate in the Jefferies Virtual Fitness & Wellness Summit Business Wire
Aug-25-22 07:00AM	Clinical Data from the LIGHT-UP Study Presented at the International Congress of Endocrinology Suggests New Gelesis Oral Hydrogel May Improve Insulin Sensitivity and Favorably Impact Metabolic Syndrome Business Wire +12.96%
Aug-17-22 03:19PM	REPLAY: Fight Obesity With Biotech Gelesis CEO, CFO in Fireside Chat IPO-Edge.com
08:00AM	Gelesis to Participate in Fireside Chat with IPO Edge Today at 2:00 PM ET Business Wire
Aug-16-22 11:59AM	Arming Consumers to Fight Obesity with Biotech Join CEO and CFO of Gelesis in Fireside Chat Wednesday at 2 ET IPO-Edge.com
Aug-15-22 09:00AM	Biotech to Lose Weight Join CEO and CFO of Gelesis in Fireside Chat Wednesday at 2 ET IPO-Edge.com -14.72%
07:00AM	Gelesis Reports Second Quarter 2022 Results Business Wire
04:05PM	Loading…
Aug-04-22 04:05PM	Gelesis to Report Second Quarter 2022 Financial Results on August 15, 2022 Business Wire
Jun-21-22 06:30AM	Gelesis Announces Additional $15 Million Pre-Order for Plenity®, Bringing Total Pre-Paid Orders from Ro for Plenity to $55 Million Business Wire
Jun-05-22 08:00AM	Over the Past Decade, Person-First Language Was Used in Only About Half of Diabetes-Focused Articles and Fewer than 1% of Obesity Articles, Finds New Study Business Wire
Jun-04-22 11:00AM	Microbiota Transplantation Demonstrates How Gut Bacteria Contributes to Weight Loss and Beneficial Metabolic Effects with Gelesis Proprietary Hydrogel Business Wire
May-18-22 04:05PM	Gelesis to Participate in Upcoming Investor Conferences Business Wire
May-12-22 04:00PM	Gelesis Reports First Quarter 2022 Results Business Wire
May-09-22 06:00AM	Gelesis to Report First Quarter 2022 Financial Results on May 12, 2022 Business Wire -9.74%
May-04-22 06:31AM	Clinical Data Presented at the European Congress on Obesity 2022 Demonstrates Weight Loss With GS200 in Adults With Prediabetes and Type 2 Diabetes Business Wire
Apr-29-22 06:00AM	Gelesis Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansia, a Bacterial Species Associated with Gut Health and Weight Loss, in New Study Business Wire
Mar-24-22 04:00PM	Gelesis® Reports Fiscal Year 2021 Results and Fiscal Year 2022 Financial Outlook Business Wire -6.34%
Mar-17-22 06:30AM	Gelesis to Report Full Year 2021 Financial Results on March 24, 2022 Business Wire
Mar-16-22 06:30AM	Gelesis® Releases Preliminary National Launch Results for Plenity®: Record-Breaking Levels of Prescriptions and Online Traffic Business Wire
Jan-31-22 06:45AM	Plenity® National Media Campaign Kicking Off Today Challenges Restrictive Dieting Norms Business Wire +7.82%
Jan-19-22 06:24AM	The one-year earnings decline has likely contributed toGelesis Holdings' (NYSE:GLS) shareholders losses of 42% over that period Simply Wall St. -7.20%

Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KUCHERLAPATI RAJU S	Director	Nov 21	Buy	0.45	92,000	41,400	190,264	Nov 22 06:20 PM
KUCHERLAPATI RAJU S	Director	Nov 18	Buy	0.39	8,000	3,120	98,264	Nov 22 06:20 PM
KUCHERLAPATI RAJU S	Director	Jun 15	Buy	1.95	24,625	47,947	90,264	Jun 17 10:46 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience